Summary of findings 5. Deferasirox and deferoxamine compared to deferoxamine in people with transfusion‐dependent thalassemia.
| Deferasirox and deferoxamine compared to deferoxamine in people with transfusion‐dependent thalassemia | ||||||
| Patient or population: people with transfusion‐dependent thalassemia Setting:outpatient care Intervention: deferasirox and deferoxamine Comparison: deferoxamine | ||||||
| Outcomes | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | № of participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Risk with deferoxamine | Risk with deferasirox and deferoxamine | |||||
| Mortality at any time point | Study population | not estimable | 94 (1 RCT) | ⊕⊕⊝⊝ LOW 1 | ||
| 0 per 1.000 | 0 per 1.000 (0 to 0) | |||||
| Responder analysis | Not measured | NA | ||||
| Serum ferritin (ng/mL) ‐ mean at end of study | MD 87.84 ng/mL higher (612.23 lower to 787.91 higher) | ‐ | 94 (1 RCT) | ⊕⊝⊝⊝ VERY LOW 2 3 | ||
| LIC | Not measured | NA | ||||
| Satisfaction with treatment | Not measured | NA | ||||
| Adherence: Discontinuations | Study population | not estimable | 94 (1 RCT) | ⊕⊝⊝⊝ VERY LOW 1 2 | ||
| 0 per 1.000 | 0 per 1.000 (0 to 0) | |||||
| AE: serum creatinine increased | Not reported | NA | Serum creatinine was measured in Molavi 2014, but no results were reported. | |||
| *The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). AE: adverse events; CI: confidence interval; LIC: liver iron concentration; MD: mean difference; NA: not applicable; RR: risk ratio. | ||||||
| GRADE Working Group grades of evidence High quality: we are very confident that the true effect lies close to that of the estimate of the effect Moderate quality: we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low quality: our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low quality: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | ||||||
1 Very serious imprecision: only very few participants included. 2 Serious risk of bias: assumed lack of blinding. 3 Very serious imprecision: very wide confidence interval including both benefit as well as harm.